Prophylactic or therapeutic agent for diabetes or obesity
作者： Yuzuru Eto , Reiko Yasuda
DOI:
关键词:
摘要: A medicament having an excellent CaSR agonist action which enables the prevention or treatment of diabetes obesity is provided by a composition comprising compound represented general formula (I) as defined, salt thereof.
google.com.tr 参考文章(66)
Graham J. Naylor, Bodyweight reducing method ,(1982)
Stefan Petry, Karl Schoenafinger, Guenter Mueller, Karl-Heinz Baringhaus, Substituted 3-phenyl-5-alkoxy-1,3,4-oxadiazol-2-ones, their preparation and their use as pharmaceuticals ,(2001)
Felix Karim, Qun Yin, Derek MacLean, Amos Baruch, Kanad Das, Therapeutic agents for reducing parathyroid hormone levels ,(2010)
Unmesh Shah, Timothy J. Kowalski, GPR119 Agonists for the Potential Treatment of Type 2 Diabetes and Related Metabolic Disorders Incretins and Insulin Secretion. ,vol. 84, pp. 415- 448 ,(2010) , 10.1016/B978-0-12-381517-0.00016-3
Erich Haid, August Wilhelm Wahlefeld, Fritz Stahler, Erich Bernt, Wolfgang Gruber, Gunter Weimann, γ-Glutamyl-4-nitroanilide compounds ,(1973)
Daniel T. Risch, Pete A. Betts, Fred H. Wahlquist, Bernard A. Matthys, Wayne M. Wagner, Joseph C. Tokar, Gary R. Gillingham, Valve assembly for preventing liquid ingestion and methods ,(1999)
Peter G. M. Wuts, Theodora W. Greene, Protective groups in organic synthesis ,(1981)
Kilian Waldemar Conde-Frieboes, Ulrich Sensfuss, Birgitte Schjellerup Wulff, Jesper F. Lau, Peptides for Treatment of Obesity ,(2009)
Takeaki Ohsu, Sen Takeshita, Yuzuru Eto, Yusuke Amino, Calcium receptor activator ,(2006)